Dr. Carey on Treating Triple-Negative Breast Cancer

Lisa A. Carey, MD
Published: Saturday, Feb 28, 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Carey says the main challenge in treating triple-negative breast cancer is that physicians are limited to chemotherapy outside of clinical trials. However, there are relatively low-toxicity chemotherapy regimens that are used in the treatment of these patients.

Triple-negative breast cancer tends to behave like other subsets where taxanes are effective, and it has been shown that platinum drugs are as effective as taxanes in the first-line setting, Carey says.

Even though treatment in the space is limited to chemotherapy, Carey says there are 4-5 agents that can be used for the treatment of triple-negative breast cancer.

<<< View more from the 32nd Annual Miami Breast Cancer Conference

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Carey says the main challenge in treating triple-negative breast cancer is that physicians are limited to chemotherapy outside of clinical trials. However, there are relatively low-toxicity chemotherapy regimens that are used in the treatment of these patients.

Triple-negative breast cancer tends to behave like other subsets where taxanes are effective, and it has been shown that platinum drugs are as effective as taxanes in the first-line setting, Carey says.

Even though treatment in the space is limited to chemotherapy, Carey says there are 4-5 agents that can be used for the treatment of triple-negative breast cancer.

<<< View more from the 32nd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x